BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 14500353)

  • 21. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
    Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
    Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.
    Wilgus TA; Koki AT; Zweifel BS; Kusewitt DF; Rubal PA; Oberyszyn TM
    Mol Carcinog; 2003 Oct; 38(2):49-58. PubMed ID: 14502644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
    Chun KS; Surh YJ
    Biochem Pharmacol; 2004 Sep; 68(6):1089-100. PubMed ID: 15313405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
    Shin YK; Park JS; Kim HS; Jun HJ; Kim GE; Suh CO; Yun YS; Pyo H
    Cancer Res; 2005 Oct; 65(20):9501-9. PubMed ID: 16230415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
    J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells.
    Song YC; Kim SH; Juhnn YS; Song YS
    Ann N Y Acad Sci; 2007 Jan; 1095():26-34. PubMed ID: 17404014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.
    Williams CS; Watson AJ; Sheng H; Helou R; Shao J; DuBois RN
    Cancer Res; 2000 Nov; 60(21):6045-51. PubMed ID: 11085526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
    Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
    Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
    Lin J; Hsiao PW; Chiu TH; Chao JI
    Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
    Suh YJ; Chada S; McKenzie T; Liu Y; Swisher SG; Lucci A; Hunt KK
    Surgery; 2005 Sep; 138(3):422-30. PubMed ID: 16213894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.
    Kim SH; Kim SH; Song YC; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():635-41. PubMed ID: 19723114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression.
    Levitt RJ; Buckley J; Blouin MJ; Schaub B; Triche TJ; Pollak M
    Biochem Biophys Res Commun; 2004 Apr; 316(2):421-8. PubMed ID: 15020235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways.
    Ogunwobi OO; Beales IL
    Regul Pept; 2006 Mar; 134(1):1-8. PubMed ID: 16169610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
    Bijman MN; Hermelink CA; van Berkel MP; Laan AC; Janmaat ML; Peters GJ; Boven E
    Biochem Pharmacol; 2008 Jan; 75(2):427-37. PubMed ID: 17936723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines.
    Hida T; Kozaki K; Muramatsu H; Masuda A; Shimizu S; Mitsudomi T; Sugiura T; Ogawa M; Takahashi T
    Clin Cancer Res; 2000 May; 6(5):2006-11. PubMed ID: 10815926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells.
    Kase S; Osaki M; Honjo S; Takeda A; Adachi K; Araki K; Ito H
    J Exp Clin Cancer Res; 2004 Jun; 23(2):301-7. PubMed ID: 15354416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective COX-2 inhibitor, NS-398, inhibits the replicative senescence of cultured dermal fibroblasts.
    Han JH; Roh MS; Park CH; Park KC; Cho KH; Kim KH; Eun HC; Chung JH
    Mech Ageing Dev; 2004 May; 125(5):359-66. PubMed ID: 15130753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment.
    Swamy MV; Cooma I; Patlolla JM; Simi B; Reddy BS; Rao CV
    Mol Cancer Ther; 2004 Feb; 3(2):215-21. PubMed ID: 14985462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor.
    Hasegawa K; Ohashi Y; Ishikawa K; Yasue A; Kato R; Achiwa Y; Nishio E; Udagawa Y
    Int J Oncol; 2005 May; 26(5):1419-28. PubMed ID: 15809736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.